HEK293 residual DNA testing in cell and gene therapy
Sponsor
Cell and gene therapies rely on host cell lines during their development. However, before administering the final product to a patient, it is crucial to remove any traces of host cell DNA to prevent toxicity including potential oncogenic effects.
This panel discussion-based webinar will explore the rationale and regulatory requirements behind HEK293-derived residual DNA detection and removal, and explain the relative pros and cons of the various analytical tools available, including both conventional and novel methods for residual host cell DNA measurement. In doing so, the panel will deliver a blueprint for success in meeting the requirements of key global regulatory bodies, including the US FDA, thus ensuring patient safety.
Attend this webinar to learn about:
- The impact of HEK293 residual DNA contamination
- Regulatory requirements relating to residual host cell DNA measurement
- The limitations of traditional molecular detection methods and how to improve upon their sensitivity and accuracy
SPEAKERS
You might also like
Leveraging dPCR for residual DNA and viral titer quantitation in advanced therapy manufacture
Overcoming challenges in cell therapy production: rapid sterility testing
How to apply quality by design principles to cell and gene therapy release testing
